ARCALYST
Preclinical
RegeneronARCALYST is one of 28 therapeutic programs targeting Cryopyrin-Associated Periodic Syndrome. It is currently in Preclinical.
2
Indications
0
Total Trials
0
Active Trials
27
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
26 competitors in Gout
#DrugCompanyPhaseTrials
1Uloric
TakedaApproved
Zyloprim
Jazz PharmaceuticalsApproved
Colcrys
Jazz PharmaceuticalsApproved
Trexall
Jazz PharmaceuticalsApproved
Aleve
Jazz PharmaceuticalsApproved
Prevacid
TakedaApproved
Otezla
AmgenApproved
Cellcept
RocheApproved
Glucophage
EMD SeronoApproved
Rayos
RRoxane Laboratories
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for ARCALYST. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company